Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

451
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
451
Clinical Trials01:16

Clinical Trials

6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.7K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Operational research in infectious disease outbreak response: An analysis of the World Health Organization's Disease Outbreak News.

PLOS global public health·2026
Same author

Understanding infection control needs in schools: insights from Nebraska's school health staff.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Can mHealth improve migrant wellness during public health emergencies? A community-engaged qualitative study during the COVID-19 pandemic.

BMC digital health·2026
Same author

Financial Impacts of Receiving Combat Casualties during a Large-Scale Combat Operation on Civilian Hospitals in the NDMS Pilot Study.

Disaster medicine and public health preparedness·2026
Same author

Case Series: Use of Dalbavancin for Invasive Gram-Positive Infection in Children.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same author

Landscape of Current Transplant Infectious Disease Training Programs.

Transplant infectious disease : an official journal of the Transplantation Society·2025

Related Experiment Video

Updated: Jun 26, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Therapeutics Pipeline.

Lauren Sauer1, Alice Sato2, Herbert Dele Davies3

  • 1GCHS, Special Pathogen Research Network, Department of Environmental, Agricultural and Occupational Health, UNMC College of Public Health, 984355 Nebraska Medical Center, Omaha, NE, USA.

Pediatric Clinics of North America
|May 16, 2024
PubMed
Summary
This summary is machine-generated.

Developing medical countermeasures (MCMs) for children presents unique challenges due to their distinct needs. The coronavirus disease 2019 pandemic accelerated the need for a robust pediatric MCM pipeline.

Keywords:
AntiviralsDrug pipelineFormulationsMedical countermeasuresMonoclonal antibodiesPhysiologyPolyclonal preparationsTherapeutics

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.1K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.5K

Related Experiment Videos

Last Updated: Jun 26, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.1K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.5K

Area of Science:

  • Pediatric pharmacology
  • Infectious disease therapeutics
  • Public health preparedness

Background:

  • Children possess unique physiological, developmental, and psychosocial characteristics, complicating therapeutic development.
  • Pandemic and outbreak scenarios exacerbate the challenges of creating effective pediatric medical countermeasures (MCMs).
  • Past decade has seen progress, but the coronavirus disease 2019 pandemic highlighted critical gaps in pediatric MCM development.

Purpose of the Study:

  • To address the inherent challenges in developing medical countermeasures (MCMs) for pediatric populations.
  • To emphasize the necessity of a dedicated MCM pipeline for children.
  • To highlight the unique considerations required for pediatric therapeutic development during public health emergencies.

Main Methods:

  • Review of existing literature on pediatric drug development and MCMs.
  • Analysis of challenges specific to pediatric populations during health crises.
  • Examination of advancements spurred by the coronavirus disease 2019 pandemic.

Main Results:

  • Pediatric-specific physiological and developmental differences pose significant hurdles for MCM development.
  • The urgent nature of pandemics necessitates tailored approaches for pediatric MCMs.
  • The coronavirus disease 2019 pandemic underscored the need for accelerated pediatric MCM research and development.

Conclusions:

  • A robust pipeline for pediatric medical countermeasures is essential for effective public health response.
  • Addressing the unique vulnerabilities of children is paramount in therapeutic development.
  • Future efforts must prioritize pediatric considerations in the design and implementation of MCMs.